Attached files
| file | filename |
|---|---|
| EX-99.3 - EX-99.3 - Aclaris Therapeutics, Inc. | ex-99d3.htm |
| EX-99.2 - EX-99.2 - Aclaris Therapeutics, Inc. | ex-99d2.htm |
| EX-23.2 - EX-23.2 - Aclaris Therapeutics, Inc. | ex-23d2.htm |
| 8-K/A - 8-K/A - Aclaris Therapeutics, Inc. | f8-ka.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT AUDITORS
We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (No. 333-212095) and S-8 (No. 333-223922, 333-220149, 333-216703, 333-210379 and 333-207434) of Aclaris Therapeutics, Inc. of our report dated December 21, 2018 relating to the special purpose financial statements of the Rhofade® Product of Allergan plc, which appears in this Current Report on Form 8-K/A.
/s/ PricewaterhouseCoopers LLP
Florham Park, NJ
January 18, 2019